Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Where are we going with CARs?

Stephen Schuster • 7 Dec 2019
ASH 2019
General CAR-T NK-Cell Therapy

Stephen Schuster, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, talks about the future perspectives for CAR (chimeric antigen receptor) therapy and where the field is expected to move. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Stephen Schuster

1:45
Mosunetuzumab in B-NHL R/R to CAR-T
Stephen Schuster • 7 Dec 2019
1:39
Out of specification anti-CD19 CAR T-cell products in aggressive B-cell lymphomas
Stephen Schuster • 7 Dec 2019
9:26
Mosunetuzumab induces CR in B-NHL R/R to CAR-T
Stephen Schuster • 8 Dec 2019
15:07
Expert discussion on CAR-T updates in lymphoma
Caron Jacobson et al. • 11 Oct 2019

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals